Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the prostate cancer registry

Detalhes bibliográficos
Autor(a) principal: Chowdhury, Simon
Data de Publicação: 2020
Outros Autores: Bjartell, Anders, Lumen, Nicolaas, Maroto, Pablo, Paiss, Thomas, Gomez-Veiga, Francisco, Birtle, Alison, Kramer, Gero, Kalinka, Ewa, Spaëth, Dominique, Feyerabend, Susan, Matveev, Vsevolod, Lefresne, Florence, Lukac, Martin, Wapenaar, Robert, Costa, Luis
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/54629
Resumo: © The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
id RCAP_45ab5c393549bd6185303ff020795757
oai_identifier_str oai:repositorio.ul.pt:10451/54629
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the prostate cancer registry© The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Background: Metastatic prostate cancer has a 30% 5-year survival rate despite recent therapeutic advances. There is a need to improve the clinical understanding and treatment of this disease, particularly in the real-world setting and among patients who are under-represented in clinical trials. Objective: We aimed to evaluate the characteristics and clinical outcomes of patients who received their first treatment for metastatic castration-resistant prostate cancer (mCRPC) in routine clinical practice, independent of treatment used, including subgroups with baseline cardiac disease, diabetes mellitus, or visceral metastases. Patients and methods: Prospective, noninterventional analysis of patient record data in the multicenter Prostate Cancer Registry (PCR) of men with mCRPC. The data were collected in 16 countries with the aim of recruiting more than 3000 patients between 2013 and 2016. The study end date was 9 July 2018. Data evaluated included baseline characteristics, treatment exposure, and efficacy outcomes [overall survival (OS) and time to progression (TTP)] of patients treated with abiraterone acetate plus prednisone or prednisolone (collectively, "abiraterone"), enzalutamide, or docetaxel. Descriptive outcomes are reported from the overall patient population and subgroups of patients with baseline cardiovascular disease, diabetes mellitus, or visceral metastases. The treatment effects for time to progression were compared for the overall patient population. Results: The study enrollment period lasted 2.5 years, and each patient was followed for a maximum of 3 years. A total of 1874 patients in the PCR had not received previous mCRPC treatment at baseline, although they had received androgen-deprivation therapy. Prevalent co-morbidities included cardiovascular disease in 65.4% and diabetes mellitus in 17.4% of patients. Baseline characteristics suggested that patients with more advanced disease received docetaxel treatment. In the overall patient population, the median time to progression with abiraterone, enzalutamide, and docetaxel as first-line mCRPC therapy was 9.6, 10.3, and 7.6 months, respectively, and median OS was 27.1, 27.1, and 27.9 months, respectively. Outcomes in the subgroups of patients with cardiovascular disease or diabetes mellitus were similar to those of the whole population in the analysis. As expected, patients with visceral metastases had shorter TTP and OS than patients in the overall population. Conclusions: This analysis shows, for the first time, the effectiveness in parallel of first-line abiraterone, enzalutamide, and docetaxel in mCRPC, including in patients with co-morbidities such as cardiovascular disease or diabetes mellitus or in patients with visceral metastases. These real-world findings from the PCR provide meaningful information to help manage mCRPC, particularly in patients under-represented in clinical studies.Springer NatureRepositório da Universidade de LisboaChowdhury, SimonBjartell, AndersLumen, NicolaasMaroto, PabloPaiss, ThomasGomez-Veiga, FranciscoBirtle, AlisonKramer, GeroKalinka, EwaSpaëth, DominiqueFeyerabend, SusanMatveev, VsevolodLefresne, FlorenceLukac, MartinWapenaar, RobertCosta, Luis2022-09-29T14:21:30Z20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/54629engTarget Oncol. 2020 Jun;15(3):301-3151776-259610.1007/s11523-020-00720-21776-260Xinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T17:01:06Zoai:repositorio.ul.pt:10451/54629Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T22:05:25.173389Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the prostate cancer registry
title Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the prostate cancer registry
spellingShingle Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the prostate cancer registry
Chowdhury, Simon
title_short Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the prostate cancer registry
title_full Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the prostate cancer registry
title_fullStr Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the prostate cancer registry
title_full_unstemmed Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the prostate cancer registry
title_sort Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the prostate cancer registry
author Chowdhury, Simon
author_facet Chowdhury, Simon
Bjartell, Anders
Lumen, Nicolaas
Maroto, Pablo
Paiss, Thomas
Gomez-Veiga, Francisco
Birtle, Alison
Kramer, Gero
Kalinka, Ewa
Spaëth, Dominique
Feyerabend, Susan
Matveev, Vsevolod
Lefresne, Florence
Lukac, Martin
Wapenaar, Robert
Costa, Luis
author_role author
author2 Bjartell, Anders
Lumen, Nicolaas
Maroto, Pablo
Paiss, Thomas
Gomez-Veiga, Francisco
Birtle, Alison
Kramer, Gero
Kalinka, Ewa
Spaëth, Dominique
Feyerabend, Susan
Matveev, Vsevolod
Lefresne, Florence
Lukac, Martin
Wapenaar, Robert
Costa, Luis
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Chowdhury, Simon
Bjartell, Anders
Lumen, Nicolaas
Maroto, Pablo
Paiss, Thomas
Gomez-Veiga, Francisco
Birtle, Alison
Kramer, Gero
Kalinka, Ewa
Spaëth, Dominique
Feyerabend, Susan
Matveev, Vsevolod
Lefresne, Florence
Lukac, Martin
Wapenaar, Robert
Costa, Luis
description © The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
publishDate 2020
dc.date.none.fl_str_mv 2020
2020-01-01T00:00:00Z
2022-09-29T14:21:30Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/54629
url http://hdl.handle.net/10451/54629
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Target Oncol. 2020 Jun;15(3):301-315
1776-2596
10.1007/s11523-020-00720-2
1776-260X
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer Nature
publisher.none.fl_str_mv Springer Nature
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134606197260288

Registros relacionados